Iron Deficiency Anemia Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapy Type (Oral Iron Therapy, Parenteral Iron Therapy, Red Blood Cell Transfusion, Others), By Therapy Areas (Obstetrics and Gynecology, Oncology, Congestive Heart Failure (CHF), Inflammatory Bowel Disease, Renal, Others), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 5.89 Billion
CAGR (2026-2031)	7.68%
Fastest Growing Segment	Inflammatory Bowel Disease
Largest Market	North America
Market Size (2031)	USD 9.18 Billion

Market Overview

The Global Iron Deficiency Anemia Market will grow from USD 5.89 Billion in 2025 to USD 9.18 Billion by 2031 at a 7.68% CAGR. The Global Iron Deficiency Anemia Market comprises therapeutic solutions, specifically oral and parenteral iron formulations, designed to replenish iron stores and normalize hemoglobin levels in affected patients. Market growth is primarily driven by the escalating burden of chronic diseases and maternal health conditions necessitating consistent hematological intervention, alongside increasing awareness of nutritional deficits. According to the World Health Organization, in 2025, updated estimates revealed that 30.7% of women aged 15-49 years were affected by anemia, underscoring the vast patient population sustaining therapeutic demand.

Nevertheless, market expansion is significantly impeded by the adverse event profiles associated with standard treatments. Oral iron frequently induces gastrointestinal intolerance resulting in non-compliance, while intravenous administration carries risks of hypersensitivity and requires clinical supervision, thereby increasing healthcare complexities. These safety and logistical hurdles significantly limit patient adherence and restrict the widespread adoption of effective iron replacement therapies, particularly in resource-constrained healthcare settings where monitoring is limited.

Key Market Drivers

The increasing burden of Chronic Kidney Disease (CKD) and gastrointestinal disorders acts as a primary catalyst for market expansion, as these conditions frequently disrupt iron absorption and utilization. Patients undergoing dialysis or suffering from inflammatory bowel diseases often require consistent iron supplementation to manage hemoglobin levels, thereby creating sustained demand for both intravenous and oral therapeutics. This reliance on pharmacological intervention is evident in the commercial performance of specialized renal treatments. According to Akebia Therapeutics, March 2025, in the 'Fourth Quarter and Full Year 2024 Financial Results', net product revenues for Auryxia, a ferric citrate formulation utilized in the renal care space, reached $152.2 million for the full year 2024. Such financial indicators reflect the critical necessity of iron replacement therapies in managing chronic comorbidities.

Simultaneously, a sharpened focus on maternal health and the management of pregnancy-related anemia is significantly propelling therapeutic adoption. Governmental and health organization mandates are increasingly prioritizing the screening and treatment of iron deficiency in expectant mothers to prevent adverse birth outcomes and maternal mortality. According to the World Health Organization, 2025, in the 'WHO Global Anaemia estimates, 2025 Edition', it was reported that 35.5% of pregnant women aged 15-49 years worldwide were affected by anemia in 2023, highlighting the urgent scale of clinical need. Consequently, the uptake of novel oral formulations designed to improve compliance in this and other populations has surged. For instance, according to Shield Therapeutics, February 2025, in their 'Unaudited full year trading update', revenues for the oral iron drug Accrufer grew 153% year-over-year to $29.3 million in 2024, demonstrating rapid market penetration.

Download Free Sample Report

Key Market Challenges

The adverse event profiles associated with standard iron replacement therapies pose a direct and significant barrier to the expansion of the Global Iron Deficiency Anemia Market. Oral iron formulations, which constitute the primary treatment modality, frequently induce severe gastrointestinal distress, including nausea, constipation, and abdominal pain. These debilitating side effects often result in patient non-compliance and premature discontinuation of therapy, thereby reducing the volume of completed treatment courses. Furthermore, intravenous iron administration involves risks of hypersensitivity reactions and necessitates infusion in clinically monitored environments, creating logistical obstacles that limit product uptake in resource-constrained settings where such infrastructure is scarce.

This safety and tolerability gap prevents the market from fully capitalizing on the urgent therapeutic needs of high-risk demographics. The magnitude of this missed opportunity is substantial when considering the prevalence of the condition among vulnerable groups. According to the World Health Organization, in 2025, updated estimates indicated that 35.5% of pregnant women aged 15-49 years globally were affected by anemia. The inability of current standard-of-care options to provide a seamless, well-tolerated regimen for this vast patient population restricts the widespread adoption of effective iron therapies and hampers overall market revenue potential.

Key Market Trends

The market is currently witnessing an accelerated adoption of high-dose intravenous iron therapies, driven by the clinical necessity to streamline treatment protocols and minimize hospital visits. Unlike traditional lower-dose regimens that require multiple infusion sessions, high-dose formulations enable complete iron repletion in a single administration, significantly enhancing outpatient workflow efficiency and patient convenience. This strategic shift towards optimized delivery systems is directly reflected in the robust financial performance of specialized manufacturers. According to Pharmacosmos, June 2025, in a 'Press Release', the company reported that its annual revenue surpassed DKK 3 billion, a commercial milestone attributed to the sustained global uptake and market penetration of its high-dose monoferric formulation.

Simultaneously, the competitive landscape is being fundamentally reshaped by the market entry and expansion of biosimilar iron therapeutics, triggered by the expiration of patents for established branded intravenous treatments. The introduction of these bioequivalent alternatives is compelling incumbents to adapt their strategies while providing healthcare systems with cost-effective options for large-scale anemia management. This influx of generic challengers is creating a more fragmented market environment, yet demand remains resilient due to the essential nature of these therapies. According to CSL Limited, February 2025, in the 'Half Year Results Announcement', iron product sales reached $527 million for the period, achieving volume growth even amidst the intensifying pressure of generic competition on its flagship brands.

Segmental Insights

The Inflammatory Bowel Disease segment is projected to register the fastest growth within the Global Iron Deficiency Anemia Market. This expansion is primarily driven by the increasing prevalence of conditions such as Crohn's disease and ulcerative colitis, which lead to chronic inflammation and impaired iron absorption. As these disorders frequently result in significant blood loss, there is a heightened clinical necessity for effective iron replacement therapies. Consequently, healthcare providers are increasingly prioritizing targeted treatments to manage anemia in these patients, thereby sustaining the rapid expansion of this specific market segment.

Regional Insights

North America leads the Global Iron Deficiency Anemia Market, primarily driven by its advanced healthcare infrastructure and substantial healthcare expenditure. This dominance is supported by the strong presence of major pharmaceutical companies and widespread awareness regarding anemia management. The US Food and Drug Administration (FDA) plays a pivotal role by facilitating the approval of advanced intravenous and oral iron therapies, ensuring rapid market access for innovative treatments. Additionally, favorable reimbursement policies and routine screening programs encourage early diagnosis, effectively sustaining the region's commanding position in the global landscape.

Recent Developments

• In May 2025, SteinCares and Pharmacosmos announced the launch of Monofer (ferric derisomaltose) across six Latin American markets, including Chile, Ecuador, Panama, Guatemala, Costa Rica, and the Dominican Republic. This strategic expansion was aimed at delivering an efficient intravenous iron replacement therapy to patients in the region suffering from iron deficiency and iron deficiency anemia. The collaboration utilized SteinCares’ established specialty healthcare infrastructure to facilitate rapid market entry and distribution. Both companies emphasized that this rollout would enhance the standard of care by providing a treatment option capable of correcting iron deficits in a single hospital visit, thereby improving compliance and clinical outcomes for patients.
• In August 2024, Shield Therapeutics plc received regulatory approval from Health Canada for Accrufer (ferric maltol), an oral pharmaceutical product for the treatment of adults with iron deficiency, with or without anemia. This approval allowed the company to introduce its lead asset into the Canadian market, offering a novel therapeutic alternative for patients who historically struggled with the side effects of conventional oral iron supplements. The company described the authorization as a pivotal development in its international commercial strategy, designed to meet significant unmet medical needs in the management of iron deficiency anemia outside of its existing markets in the United States and Europe.
• In June 2024, Menarini Asia-Pacific expanded its strategic collaboration with Pharmacosmos to include exclusive rights for the commercialization of MonoFer (ferric derisomaltose) in Singapore and Malaysia. This agreement built upon a successful existing partnership between the two companies in Australia and aimed to address the high prevalence of iron deficiency anemia in Southeast Asia. Under the terms of the expansion, Menarini Asia-Pacific assumed full responsibility for the marketing, sales, and distribution of the high-dose intravenous iron injection in the new territories. The companies highlighted that this initiative would leverage local market expertise to improve patient access to innovative iron deficiency treatments across the region.
• In March 2024, CSL Vifor announced that Health Canada authorized Ferinject (ferric carboxymaltose) for the intravenous treatment of iron deficiency anemia in adult and pediatric patients one year of age and older. This regulatory approval provided a new option for patients who had an intolerance to oral iron preparations or for whom such treatments were ineffective. The authorization also covered the treatment of iron deficiency in adult patients with heart failure and New York Heart Association class II/III to improve exercise capacity. The company noted that this approval significantly expanded the reach of their intravenous iron therapy, reinforcing their portfolio in the global iron deficiency anemia market.

Key Market Players

• AbbVie Inc.
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Novartis AG
• Amgen Inc.
• Bayer AG
• Fresenius Kabi AG
• Vifor Pharma Group
• Glenmark Pharmaceuticals Ltd.
• Dr. Reddy’s Laboratories Ltd.

By Therapy Type	By Therapy Areas	By End User	By Region
Oral Iron Therapy Parenteral Iron Therapy Red Blood Cell Transfusion Others	Obstetrics and Gynecology Oncology Congestive Heart Failure (CHF) Inflammatory Bowel Disease Renal Others	Hospitals & Clinics Ambulatory Care Centers Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Iron Deficiency Anemia Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Iron Deficiency Anemia Market, By Therapy Type:

• Oral Iron Therapy
• Parenteral Iron Therapy
• Red Blood Cell Transfusion
• Others

• Iron Deficiency Anemia Market, By Therapy Areas:

• Obstetrics and Gynecology
• Oncology
• Congestive Heart Failure (CHF)
• Inflammatory Bowel Disease
• Renal
• Others

• Iron Deficiency Anemia Market, By End User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

• Iron Deficiency Anemia Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE